21
August 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Strategic Collaboration with
SINTEF for Advanced Chronic Wound Management
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector, is pleased to announce a strategic
collaboration with SINTEF, one of Europe's largest independent
research organisations, to address the critical and unmet clinical
challenge of chronic wound management, through nano-formulations as
part of the Company's ongoing expansion into new therapeutic
areas.
Argent Biopharma hopes that this
collaboration with SINTEF will lead to significant advancements in
the treatment of chronic wounds, ultimately improving the quality
of life for patients suffering from this challenging condition. The
Company looks forward to updating shareholders as the project
progresses.
Project overview
Chronic wounds represent a
significant clinical issue globally, causing extreme patient
suffering and affecting substantial numbers of individuals. These
wounds present complex challenges, including severe symptoms,
antibiotic- resistant infections, impenetrable biofilms, and
deteriorating local tissue health.
Argent BioPharma intends for this
study to address multiple facets of this complex condition as
detailed below:
·
Identification
and Selection of Novel Anti-Microbial Active
Ingredients:
o Experiments performed with SINTEF will initially focus on
identifying and selecting the antimicrobial activities of a range
of repurposed polypharmacological agents endowed with multiple
medically beneficial activities.
·
Improving Local
Tissue Health and Symptomatic Relief:
o SINTEF will further investigate the chosen range of active
ingredients for their anti-biofilm, skin-health modifying and
symptom alleviating functions.
·
Optimizing
nano-formulations of the selected active ingredients to enhance the
derived medical benefits:
o The
composition of the particles will be modified in response to the
efficacy observed in the course of development, simultaneously with
modification of their additional pharmacological
features.
The collaboration will be targeting
chronic wound infections with an array of various nano-encapsulated
active ingredients. The precise selection and dosing of these
active ingredients will be methodically evaluated. The greater part
of the ingredients have not served previously as designated
anti-microbial agents, thus aligning with antimicrobial
stewardship.
A significant aspect of this project
is the design of nano-formulations for the selected agents which
are intended to be identified in the initial screening experiments.
Nano-formulation is expected to enhance the pharmacological
characteristics and efficacy of the resulting preparation via
improved drug delivery, increased penetration through biofilms, and
sustained release of active compounds, thereby addressing the
challenges posed by antibiotic resistance and local tissue health
deterioration.
All costs applicable to the project
will be incurred by Argent BioPharma, although, it is not
anticipated that these costs will have a material impact on the
Company's ongoing expenses. Additionally, Argent BioPharma will
retain ownership of all project results, including any intellectual
property developed.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent
BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the central nervous system
("CNS") and Immunology treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma
About SINTEF
SINTEF is one of Europe's largest
research institutes, with multidisciplinary expertise within
technology, natural sciences and social sciences. SINTEF is an
independent foundation which, since 1950, has created innovation
through development and research assignments for business and the
public sector at home and abroad.
